|
Patent landscape, scope, and claims: |
United States Patent 10,792,262 (Baclofen + Poly(butylmethacrylate-co-(2-dimethylaminoethyl)methacrylate-co-methyl methacrylate) Stabilizer): Claim Scope, Strength, and US Patent Landscape
Executive summary: U.S. Patent 10,792,262 is centered on a specific solid baclofen formulation architecture: baclofen (or pharmaceutically acceptable salts) combined in a stabilizer polymer matrix using poly(butylmethacrylate-co-(2-dimethylaminoethyl)methacrylate-co-methyl methacrylate) at a stabilizer:baclofen weight ratio of 1.5:1 to 10:1, including sub-ranges and explicit performance thresholds tied to 4-CPP formation control (and, in some claims, lactam formation reduction). The claims are structured as a layered estate: composition claims, manufacturing process claims (wet/dry granulation, compacting/slugging, coating), and use claims (treating spasticity and shelf-life extension via 4-CPP suppression). The practical scope is narrow on polymer identity and ratio but broad on where baclofen sits in the matrix (dispersed or intimately mixed) and on formulation embodiment (solid dosage form; with optional excipients and saliva-forming agents).
What does US Patent 10,792,262 claim cover for baclofen stabilization?
Core protected subject matter (headline):
A pharmaceutical composition where baclofen is combined with a specific polymer stabilizer in a matrix at a defined stabilizer:baclofen weight ratio.
Claim 1: composition of baclofen + specific polymer at defined ratio
Claim 1 requires all of the following:
- Active ingredient: baclofen or its pharmaceutically acceptable salts
- Stabilizer polymer identity: poly(butylmethacrylate-co-(2-dimethylaminoethyl)methacrylate-co-methyl methacrylate)
- Weight ratio: stabilizer:active ingredient = 1.5:1 to 10:1
- Structure requirement: active ingredient and stabilizer are present in a matrix
Scope implications:
- The claim is polymer-identity anchored. Changing polymer chemistry or using a different stabilizing polymer moves outside literal scope.
- The claim is ratio anchored. Even with the same polymer, formulations outside 1.5:1–10:1 avoid Claim 1 literal coverage.
- The matrix language (“present in a matrix”; “dispersed” vs “intimately mixed” in dependent claims) provides flexibility in internal morphology, but the stabilizer must still be present as the stabilizing polymer phase in the formulation.
Claims 2–4: morphology and tighter ratio ranges
- Claim 2: active ingredient is dispersed throughout a matrix of stabilizer
- Claim 3: active ingredient and stabilizer are intimately mixed in a matrix formulation
- Claim 4: tighter ratio 1.8:1 to 7.2:1
Scope implications:
- The “dispersed” and “intimately mixed” dependent claims broaden coverage of internal mixing state, but both remain confined to the same polymer and ratio constraints.
- Claim 4 creates a second numerical “fence” within Claim 1. Formulations between 1.5:1–1.8:1 or 7.2:1–10:1 may still fall under Claim 1, but not Claim 4.
Claims 5–9: optional excipient layer (including saliva-forming agents)
- Claim 5: adds one or more excipients among: xylitol, calcium stearate, colloidal silicon dioxide, talc, flavoring
- Claim 6: further comprising a saliva-forming agent
- Claim 7–9: other excipients via glidants, lubricants, fillers, sweeteners, taste-masking agents, disintegrants, saliva-forming agents, binding agents, or flavorings; and specific examples including xylitol, mannitol, saccharin sodium, hypromellose, crospovidone, calcium stearate, colloidal silicon dioxide, talc, flavoring
Scope implications:
- These claims allow formulation variation without changing the protected core (baclofen + that polymer + ratio + matrix).
- A competitor using different excipients can still potentially infringe Claims 1–4 and 10–17, but might avoid the narrower excipient-specific dependents if the excipient set differs.
Claim 10: solid dosage form
- Composition is in a solid dosage form.
Scope implications:
- Keeps the claim aimed at solid oral forms (e.g., tablets/granules/possibly chewable or orally disintegrating designs depending on the rest of the dossier), not liquids or other formats.
How broad are the manufacturing claims in US Patent 10,792,262?
The manufacturing section adds process guards that can matter in enforcement, licensing, and generic design.
Claims 11–16: methods of making and forming the solid dosage
- Claim 11: method includes intimately mixing active ingredient and stabilizer
- Claim 12: intimately mixing comprises at least one of wet granulation or dry granulation
- Claim 13: wet granulation embodiment: dry blending, then adding solvent, then granulating
- Claim 14: dry blending embodiment
- Claim 15: further comprising dry compacting or slugging to form a solid dosage form
- Claim 16: further comprising coating the solid dosage form
Scope implications:
- These claims are method-structured, so a competitor could attempt design-around by altering manufacturing steps (e.g., using melt-based methods, extrusion, different mixing regimes, or post-injection polymer incorporation) while still making an end product that could be composition-infringing. Enforcement strategy often chooses the easiest infringement route: product (composition) first, process second.
- Claim 11’s “intimately mixing” is still likely read to cover standard pharmaceutical mixing sufficient to achieve the claimed matrix distribution.
What therapeutic and stability-use claims exist in US Patent 10,792,262?
The use claims create additional grounds for enforcement: one for clinical indication, one for chemical stability.
Claim 17: method of treating spasticity
- Administering an effective amount of Claim 1 composition to treat spasticity
Scope implications:
- The medical use is classic for baclofen. If baclofen is already approved/known for spasticity, this dependent claim tends to rely on the proprietary formulation for the patentable tie.
- This claim can be valuable for companies selling the polymer-stabilized product under label expansion or expanded distribution.
Claims 18–20: controlling lactam formation via formulation mixing
- Claim 18: method of reducing lactam formation in a baclofen formulation by intimately mixing baclofen (or salt) with the same polymer at the same ratio 1.5:1 to 10:1
- Claim 19: baclofen is micronized
- Claim 20: further milling to reduce particle size before mixing
Scope implications:
- These dependents can cover product versions that use particle-size engineering to reduce degradation pathways and/or improve uniformity.
- If a generic uses the same polymer and ratio but does not micronize/mill (or does so differently), it may still infringe Claim 18 via product mixing, depending on how “intimately mixing” and the final formulation are proven.
Claims 21–23: shelf-life extension with explicit 4-CPP performance limits
- Claim 21: increasing shelf life by reducing formation of 4-(4-chlorophenyl)-2-pyrrolidine (4-CPP) via intimate mixing into a solid baclofen formulation using the same polymer and ratio
- Claim 22: 4-CPP increases by no more than 0.2% after 6 months at 40°C/75% RH
- Claim 23: tighter: no more than 0.1% after 6 months at 40°C/75% RH
Scope implications:
- These claims turn performance into a limiting element. In litigation, they raise the evidentiary burden: the accused product’s stability protocol and measured 4-CPP growth become central.
- The explicit stability condition makes it easier to standardize testing and expert comparison.
What is the infringement “fence line” created by the polymer ratio and matrix requirements?
The most important literal limitations across the composition claims are:
- Polymer identity: poly(butylmethacrylate-co-(2-dimethylaminoethyl)methacrylate-co-methyl methacrylate)
- Ratio: stabilizer:baclofen between 1.5:1 and 10:1 (and 1.8:1–7.2:1 in Claim 4)
- Matrix presence: baclofen and polymer are present as a matrix, including “dispersed” or “intimately mixed” embodiments
- Solid dosage form (Claim 10 and method contexts)
- For performance dependents: meeting 4-CPP limits under defined storage conditions
Design-around pathways (high level, based on claim structure):
- Use a different stabilizer polymer or a modified copolymer not captured by the exact formula/name.
- Use the same polymer but change the stabilizer:baclofen ratio outside the claimed range.
- Keep polymer and ratio within range but change how the polymer is incorporated so it is not “present in a matrix” (a fact question).
- For stability-performance dependents, achieve shelf-life without meeting the stated 4-CPP numerical criteria, even if reduction occurs.
How does US Patent 10,792,262 compare with other baclofen degradation-control strategies (conceptually)?
This patent is explicitly framed around solid-state chemical stabilization for baclofen, targeting formation of 4-CPP (a lactam-related degradation product). The patent’s claim architecture indicates:
- A polymer-based stabilization method, not:
- purely moisture barrier packaging,
- pH modifiers,
- or traditional antioxidant stabilizers.
The claims also emphasize formulation uniformity and particle size, indicating that degradation control is tied to both distribution and interfacial microenvironment in the solid.
US patent landscape: what other patents typically surround baclofen stability and polymer excipients?
A complete, jurisdiction-grade landscape requires Orange Book listings, application publications, and family members. That cannot be produced from the claim text alone because U.S. Patent 10,792,262’s:
- assignee,
- earliest priority,
- related family members,
- prosecution history,
- and citations/forward citations
are not provided here.
Accordingly, a complete patent-by-patent landscape cannot be generated from the supplied information alone.
What is the likely remaining exclusivity timeline for US Patent 10,792,262?
No filing, priority, or expiration data is included in the provided content. Without:
- earliest priority date,
- patent term adjustments (PTA),
- terminal disclaimers,
- or any related pediatric exclusivity,
a timeline cannot be stated accurately.
What Orange Book status would the baclofen formulation need to have to matter commercially?
Claim scope is directly tied to a stabilized baclofen formulation in solid dosage form. Orange Book relevance would turn on:
- whether this formulation is tied to an approved drug product,
- and whether the patent is listed for that NDA ANDA.
No Orange Book record, NDA/ANDA number, or listing details are provided. A field-ready Orange Book status determination cannot be produced from the claim text alone.
Commercial and litigation risk: where would generics face the highest barriers?
Highest barrier: matching polymer identity + ratio
If a generic does not use the same polymer (or uses it outside the defined ratio), it can potentially avoid multiple composition and method claims simultaneously.
Second barrier: matrix incorporation and process
Even with the same polymer and ratio, the “matrix” limitation and manufacturing “intimately mixing” steps can drive expert disputes. If a generic uses different manufacturing steps, the composition claims may still be asserted, but the method claims may be harder to prove.
Highest evidentiary dispute: 4-CPP shelf-life limits
Claims 21–23 use explicit accelerated stability metrics. This typically becomes the battleground:
- formulation scientists will rerun stability,
- experts will tie 4-CPP assays to formulation design,
- and recordkeeping will be critical for comparing protocols.
Key Takeaways
- US Patent 10,792,262 protects a specific baclofen solid formulation: baclofen (or salts) in a matrix with a defined polymer stabilizer poly(butylmethacrylate-co-(2-dimethylaminoethyl)methacrylate-co-methyl methacrylate) at stabilizer:baclofen 1.5:1 to 10:1.
- Dependent claim set expands scope to internal distribution (dispersed vs intimately mixed), solid dosage formation, and optional excipient sets including xylitol, calcium stearate, silica, talc, flavor, and saliva-forming agents.
- The patent includes manufacturing process claims centered on wet/dry granulation, dry compacting/slugging, and coating.
- The patent includes use claims for spasticity treatment and chemical stabilization via reduced lactam formation.
- The strongest technical enforcement hooks are the 4-CPP shelf-life dependents: no more than 0.2% or 0.1% increase after 6 months at 40°C/75% RH.
FAQs
-
Do Claims 2–3 require a specific particle size of baclofen?
No. Those claims require dispersion vs intimate mixing in a matrix, while particle size appears in separate dependent claims tied to the lactam/shelf-life embodiments.
-
Is the polymer ratio limitation required for every claim in the patent?
The ratio is explicitly recited across the independent composition claim (Claim 1) and appears in the dependent composition claims and the method of reducing lactam formation and shelf-life claims.
-
Can a product infringe if it contains baclofen salts rather than free baclofen?
Yes. Claim 1 covers baclofen and pharmaceutically acceptable salts, and the method claims similarly cover baclofen or its salts.
-
How can 4-CPP claims be evaluated in enforcement?
They are tied to specific accelerated storage conditions and numerical performance thresholds, making the formulation’s stability profile and testing protocol central.
-
Would changing excipients avoid infringement?
Changing excipients can avoid excipient-specific dependents (Claims 5–9), but it does not avoid the core composition and method limitations if polymer identity, ratio, and matrix requirements are met.
References (APA)
No sources were provided or cited beyond the claim text included in the prompt.
More… ↓
⤷ Start Trial
|
